臨床検査67巻10号

2023年10月発行

増大号 肝疾患　臨床検査でどう迫る？ 4章　肝腫瘍

臨床検査を用いた肝癌の予後予測

著者： 平岡淳¹

所属機関： ¹愛媛県立中央病院消化器内科

ページ範囲：P.1208 - P.1211

はじめに

　肝細胞癌（hepatocellular carcinoma：HCC）の予後に腫瘍進行度と肝予備能が大きく関与する．肝予備能評価法としてChild-Pugh分類（以下，CP分類）や肝障害度（liver damage：LD）が用いられてきた．近年のウイルス性肝炎治療の進歩で肝予備能良好なHCCの割合が増加してきている．より詳細な肝予備能評価法としてアルブミンと総ビリルビンのみを使用したALBI（albumin-bilirubin）スコア/グレードや4段階評価のmALBI（modified ALBI）グレードの有用性が報告されている．

参考文献

1）Kudo M, et al：Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology　40：1396-1405，2004

2）Pugh RN, et al：Transection of the oesophagus for bleeding oesophageal varices. Br J Surg　60：646-649，1973

3）Makuuchi M, et al：Surgery for small liver cancers. Semin Surg Oncol　9：298-304，1993

4）Miyagawa S, et al：Criteria for safe hepatic resection. Am J Surg　169：589-594，1995

5）Kokudo N, et al：Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res　45：10.1111/hepr.12464，2015

6）Omagari K, et al：Comparison of the grade evaluated by “Liver damage” of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatol Res　34：266-272，2006

7）Tateishi R, et al：A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol　54：367-376，2019

8）Kumada T, et al：Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer　9：518-528，2020

9）Johnson PJ, et al：Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol　33：550-558，2015

10）Hiraoka A, et al：Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol　31：1031-1036，2016

11）Hiraoka A, et al：Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer　8：121-129，2019

12）Kudo M, et al：Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology　87(Suppl 1)：22-31，2014

13）Kudo M, et al：A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer　9：245-260，2020

14）Hiraoka A, et al：Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med　8：3719-3728，2019

15）Kobayashi K, et al：Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer　11：48-60，2021

16）Hiraoka A, et al：Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology　97：277-285，2019

17）Tanaka T, et al：Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res　52：773-783，2022

18）Khabbaz RC, et al：Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Do Not Predict Survival After Transjugular Intrahepatic Portosystemic Shunt Creation. Cardiovasc Intervent Radiol　41：1029-1034，2018

19）Ronald J, et al：Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. Diagn Interv Imaging　99：163-168，2018

20）Kim KM, et al：Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?. Scand J Gastroenterol　55：951-957，2020